In the current study, our group investigated the anti-tumor potential and immunomodulatory activity of a low dose of attenuated S. typhimurium and its capability to improve the therapeutic outcome of antibody-based PD-L1 inhibitors in the MC38 murine colon adenocarcinoma model. This evidence concerns the gene CD274 and neoplasm.